Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

CFTR modulator theratyping: Current status, gaps and future directions

Open access
Clancy, John Paul, Cotton, Calvin U., Donaldson, Scott H., Solomon, George M., VanDevanter, Donald R., Boyle, Michael P., Gentzsch, Martina, Nick, Jerry A., Illek, Beate, Wallenburg, John C., Sorscher, Eric J., Amaral, Margarida D., Beekman, Jeffrey M., Naren, Anjaparavanda P., Bridges, Robert J., Thomas, Philip J., Cutting, Garry, Rowe, Steven, Durmowicz, Anthony G., Mense, Martin, Boeck, Kris D., Skach, William, Penland, Christopher, Joseloff, Elizabeth, Bihler, Hermann, Mahoney, John, Borowitz, Drucy, Tuggle, Katherine L.·2019·Journal of Cystic Fibrosis

Abstract

BACKGROUND: New drugs that improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein with discreet disease-causing variants have been successfully developed for cystic fibrosis (CF) patients. Preclinical model systems have played a critical role in this process, and have the potential to inform researchers and CF healthcare providers regarding the nature of defects in rare CFTR variants, and to potentially support use of modulator therapies in new populations. METHODS: The Cystic Fibrosis Foundation (CFF) assembled a workshop of international experts to discuss the use of preclinical model systems to examine the nature of CF-causing variants in CFTR and the role of in vitro CFTR modulator testing to inform in vivo modulator use. The theme of the workshop was centered on CFTR theratyping, a term that encompasses the use of CFTR modulators to define defects in CFTR in vitro, with application to both common and rare CFTR variants. RESULTS: Several preclinical model systems were identified in various stages of maturity, ranging from the expression of CFTR variant cDNA in stable cell lines to examination of cells derived from CF patients, including the gastrointestinal tract, the respiratory tree, and the blood. Common themes included the ongoing need for standardization, validation, and defining the predictive capacity of data derived from model systems to estimate clinical outcomes from modulator-treated CF patients. CONCLUSIONS: CFTR modulator theratyping is a novel and rapidly evolving field that has the potential to identify rare CFTR variants that are responsive to approved drugs or drugs in development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcf.2018.05.004

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 291

Metadata

Authors
Clancy, J. P., Cotton, C. U., Donaldson, S. H., Solomon, G. M., VanDevanter, D. R., Boyle, M. P., Gentzsch, M., Nick, J. A., Illek, B., Wallenburg, J. C., Sorscher, E. J., Amaral, M. D., Beekman, J. M., Naren, A. P., Bridges, R. J., Thomas, P. J., Cutting, G., Rowe, S., Durmowicz, A. G., Mense, M., Boeck, K. D., Skach, W., Penland, C., Joseloff, E., Bihler, H., Mahoney, J., Borowitz, D., & Tuggle, K. L.
Venue
Journal of Cystic Fibrosis
Publisher
Elsevier BV
Published
2019-01
Volume
18
Issue
1
Pages
22-34
ISSN
1569-1993 (ISSN-L)
OpenAlex
W2808871427
Cited by
291
References
68
FWCI
19.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CFTR modulator theratyping: Current status, gaps and future directions. https://app.cochat.ai/papers/10.1016/j.jcf.2018.05.004
The paper
Clancy, J. P., Cotton, C. U., Donaldson, S. H., Solomon, G. M., VanDevanter, D. R., Boyle, M. P., Gentzsch, M., Nick, J. A., Illek, B., Wallenburg, J. C., Sorscher, E. J., Amaral, M. D., Beekman, J. M., Naren, A. P., Bridges, R. J., Thomas, P. J., Cutting, G., Rowe, S., Durmowicz, A. G., . . . Tuggle, K. L. (2019). CFTR modulator theratyping: Current status, gaps and future directions. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2018.05.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.